NCT06444815 - A Study of VET3-TGI in Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions

Solid Tumor, AdultMicrosatellite Stable Colorectal CancerHead and Neck Squamous Cell CarcinomaCervical CancerKidney CancerRenal Cell CarcinomaMelanoma Stage IVMerkel Cell Carcinoma of SkinMesotheliomaNon-small Cell Lung Cancer

Interventions

DRUG

VET3-TGI

Oncolytic vaccinia virus engineered with immunomodulatory transgenes

DRUG

Pembrolizumab

anti-pd1 antibody

Trial Locations (7)

15232

RECRUITING

UPMC- Hillman Cancer Center, Pittsburgh

33136

RECRUITING

University of Miami, Miami

46250

RECRUITING

Community Health Network, Indianapolis

75230

RECRUITING

Mary Crowley Cancer Research, Dallas

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

90033

RECRUITING

USC/Norris Comprehensive Cancer Center, Los Angeles

92868

RECRUITING

UC Irvine Health, Orange